Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 3538378

[Aplastic anemia].

B Speck
View original source ↗Export metadata ↓

Abstract

In vitro cultures of hemopoietic precursor cells and clinical studies have partly clarified the pathogenesis of aplastic anemia. The defect is located both in the hemopoietic precursor cells and in their microenvironment. The therapeutic possibilities have enormously improved. Allogeneic bone marrow transplantation remains largely limited to young patients with an HLA-identical sibling donor. In our experience successfully transplanted patients are completely cured. Mortality from rejection, graft-versus-host-disease and infection has been markedly reduced. Immune modulating therapy with ALG produces high remission rates but residual defects in hemopoietic precursor cells remain and clonal disorders such as paroxysmal nocturnal hemoglobinuria may ensue. Despite of this ALG is the treatment of choice for patients without an HLA identical sibling donor.

Explore related subjects

Anemia, AplasticAntilymphocyte SerumBone Marrow TransplantationHumansEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Speck. 1986-10-25. [Aplastic anemia].. https://pubmed.ncbi.nlm.nih.gov/3538378/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Mathematical analysis of the relative contributions of decreased production and increased peripheral destruction in idiopathic thrombocytopenic purpura and implications in splenectomy.

We utilize a model of platelet concentration kinetics and bone marrow production based on three terms (a constant loss term, a random loss term and a higher order loss term) to compare a hypoplastic bone marrow patient and a patient with Idiopathic Thrombocytopenic Purpura (ITP) for the same platelet concentration. We compare this model to published data and show that in many ITP patients there is an overall decrease in platelet production. However, for almost all cases of ITP there is an increase in peripheral platelet destruction, even in those cases where total bone marrow production is less than that in a normal individual or is severely depressed. We are able to graphically depict the variable contributions of decreased production and increased peripheral destruction in patients with ITP and hence give insight into their relative contributions in a given patient. We apply a unique feature of our model, the newly postulated destruction term proportional to the platelet concentration squared (the higher order loss term), to explain cases of antibody negative ITP. Application of our model to data on patients splenectomized as treatment for ITP shows promise in predicting which patients are likely to respond.

Anemia, Aplastic↗
PubMed2000

[Invasive aspergillosis in hematological patients].

An increasing incidence of invasive aspergillosis over the last decades is well documented in patients with haematological malignancies and is the most significant fungal infection in patients undergoing bone marrow transplantation and in aplastic anaemia. The diagnosis is difficult as clinical signs and symptoms usually are non-specific, but can be supported by frequent radiological examinations of the chest and sinuses and successive demonstrations of Aspergillus antigen in serum. The prognosis depends on the course of the underlying disease. A regeneration of the neutrophil granulocyte number is a condition for successful treatment. Early antifungal therapy is often necessary in neutropenic patients with fever and a lung infiltrate that does not remit following broad spectrum antibacterial treatment. Because of the risk of relapse after successful treatment these patients should receive prophylactic antifungal treatment during subsequent neutropenic episodes.

Anemia, Aplastic↗